Funded by the MIUR – TRANSCAN under the ERA-NET TRANSCAN 2 programme. The project has awarded to the Molecular Hematology Group at ICGEB, headed by Dimitar Efremov.
The project received EUR 123.2K funding and has 6 partners: Academisch Medisch Centrum bij de Universiteit van Amsterdam, Genuinnutzige Salzburger Landesliniken BetriebsgesmbH, Weizmann Insitute of Scinece, Ulm University, German Cancer Research Centre, and Institut Natuional de la Sante et de la Recherche Medicale as well.
Chronic Lymphocytic Leukemia (CLL) is a common cancer and the most frequent type of leukemia in Western countries. The clinical course of CLL is highly diverse, ranging from death within 2-3 years to indolent disease. The disease is driven by a combination of genetic defects and interactions of the malignant cells with various cellular elements or soluble factors from the microenvironment. The main objective of this project is to determine the role of these factors in conferring resistance to novel targeted therapies and identify rationale therapeutic combinations to prevent or overcome this resistance.
Academisch Medisch Centrum bij de Universiteit van Amsterdam; Genuinnutzige Salzburger Landesliniken BetriebsgesmbH; Weizmann Insitute of Scinece; Ulm University; German Cancer Research Centre; Institut Natuional de la Sante et de la Recherche Medicale